Cornerstone

Cornerstone Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing first-in-class therapies that exploit the metabolic differences between cancer cells and normal cells. The company's lead compound, devimistat (CPI-613), is a small molecule that targets the mitochondrial tricarboxylic acid (TCA) cycle, specifically inhibiting the pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (KGDH) complexes. This mechanism effectively disrupts the energy production of cancer cells, leading to cell death while minimizing impact on healthy tissues. Cornerstone utilizes its proprietary Altered Energy Metabolism Directed (AEMD) platform to advance a pipeline of treatments for rare and hard-to-treat cancers, including pancreatic cancer, acute myeloid leukemia, and various lymphomas.